Dysregulated ISG15 production and signaling during persistent LCMV infection drives lethal immune pathology, representing a therapeutic target during severe viral infections with pulmonary manifestations @J_Immunol@NamirShaabani@Teijaro_Labdoi.org/10.4049/jimmunol.240…
In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunotherapy enhances cancer patient response.
Learn more ⬇️
📄: scim.ag/7p1
📄: scim.ag/7p2#SciencePerspective: scim.ag/7p0
Proud of my two post-docs on their Science paper demonstrating JAK inhibitors can promote better anti-tumor responses in combination with checkpoint immunotherapy. Well done Jerry and Isa as well as all the authors! Special thanks to Dr. Veronika Bachanova for running the trial!
A new @ScienceMagazine study led by Prof. John Teijaro, PhD, found that combining ruxolitinib, an approved drug, with checkpoint inhibitors supercharged T-cell responses. This could transform #cancer treatment, especially for tough-to-treat cancers.
More: ow.ly/h7ol50SmP4I
nature.com/articles/s41589-0…
Pleased to see this one in print. What a journey with the parker lab @_chrisgparker_! Great example of merging chemical biology and immunology to generate an exciting tool to probe the immune response. Congrats to everyone involved and all the hard work!!
Excited to share the final version in
@nchembio. Lots more mechanistic insights & characterization, including our inhibitors disrupt PPIs with mTOR components & induce lysosomal degradation of SLC15A4, & more. A promising target for autoimmune conditions. nature.com/articles/s41589-0…
Belharra Therapeutics is finally ready to rise out of stealth with $130 million in capital and a multi-year collaboration with Genentech.
fiercebiotech.com/biotech/be…
Congratulations to @EOSaphire on being newly appointed as President and CEO @ljiresearch. A former graduate student and accomplished faculty member at Scripps Research, we wish her much success in her continued leadership in immunology and virology.
Great example of basic research at Scripps and the Calibr drug discovery engine coming together to advance medicines for human disease. Watch this space. Congrats to all involved!
Great day for the lab! Our collaborative work with Luke Larson's lab and Calibr came out today in Science! Congratulations to Vincent, Emily, Ying, and the whole team! We identified and characterized a novel, anti-tumor STING agonist, SR-717. Read it here: science.sciencemag.org/conte…